$ALDX News

Last published 1mo ago

1mo agoALDXAldeyra Therapeutics, Inc. Confidential Call - ALDEYRA THERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Thank you for standing by and welcome to the Aldera Therapeutics Regulatory Update and Conference Call. At this time, all participants are in a listen-only mode. After the speakers' pr
1mo agoALDXAldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye DiseaseBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the
1mo agoALDXAldeyra Therapeutics to Host Regulatory Update WebcastBusiness WireEvent Scheduled for Tuesday, September 29 at 8:00 a.m. ET Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat
4mo agoALDXLevicept Appoints Darlene Deptula-Hicks as CFOGlobeNewswireSANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the
5mo agoALDXAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of DirectorsBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of
5mo agoALDXJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - ALDEYRA THERAPEUTICS INCEarnings Call TranscriptsHello. I'm Amin Makarim, one of the biotech analysts here at Jefferies. I'm happy to introduce and welcome Todd Brady, CEO of Aldair Therapeutics. This is a fireside chat format, and thank you for joining us. My pleasure
5mo agoALDXAldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady,
6mo agoALDXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 29, 2026 in Aldeyra Therapeutics, Inc. Lawsuit - ALDXGlobeNewswireNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Shareholders who purchased shares of ALDX during the class period
6mo agoALDXREMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026GlobeNewswireNEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role of lead plaintiff
6mo agoALDXALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff RoleBusiness WireIf you have suffered a loss on your Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the
7mo agoALDX$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover LossesGlobeNewswireBOSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and certain of its executives. Investors who have
7mo agoALDXAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete
8mo agoALDXAldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady,
11mo agoALDXAldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye DiseaseBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and
12mo agoALDXAldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development WebcastBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and
1y agoALDXAldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady,
1y agoALDXAldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ETBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the company will host a
1y agoALDXAldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation MoleculesBusiness WireRelative to Baseline, Signal-Finding Molecule ADX‑629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis RASP Modulator Product Candidate Pipeline
1y agoALDXAldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal LymphomaBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of
1y agoALDXAldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis PigmentosaBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the
1y agoALDXAldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis PigmentosaBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of
1y agoALDXAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness WirePDUFA Target Action Date December 16, 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug
1y agoALDXAldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal LymphomaBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP),
1y agoALDXAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the
1y agoALDXAldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA ResubmissionBusiness WireIn a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in
1y agoALDXAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of ReproxalapBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical
1y agoALDXAldeyra Therapeutics Appoints Chip Clark to Board of DirectorsBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the
1y agoALDXKirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of InvestorsGlobeNewswireNEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). The investigation
1y agoALDXBREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the FirmGlobeNewswireBOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential securities law violations. Investors who have lost money in their Aldeyra
1y agoALDXAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseBusiness WireTop-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics,
1y agoALDXAldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
1y agoALDXAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementBusiness WirePDUFA Date is April 2, 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for
1y agoALDXAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
2y agoALDXAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that
2y agoALDXAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the
2y agoALDXAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd
2y agoALDXAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapBusiness WireNew Drug Application Resubmission Anticipated in 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat
2y agoALDXAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease
2y agoALDXAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableBusiness WireLive Webcast Scheduled to Begin at 8:00 a.m. ET Today Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat
2y agoALDXAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseBusiness WireClinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and
2y agoALDXAldeyra Therapeutics to Host Investor Roundtable Q&ABusiness WireEvent Scheduled for Thursday, June 20 at 8:00 a.m. ET Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat
2y agoALDXAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceBusiness WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady,
2y agoALDXAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseBusiness WireClinical Results and Potential New Drug Application Submission Expected in the Second Half of 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing
2y agoALDXAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayBusiness WireLive Webcast Scheduled to Begin at 9 am EDT Today Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to
2y agoALDXAldeyra Therapeutics to Host Research & Development Day on April 25, 2024Business WireAldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company